EGCG (Epigallocatechin Gallate)

Yes, but the risk is dose-dependent and context-specific. The European Food Safety Authority (EFSA 2018) systematic review analyzed case reports of liver injury following green tea extract supplementation and concluded that doses above approximately 800 mg EGCG per day are associated with elevated hepatotoxicity risk. Over 140 case reports have described acute hepatitis or liver injury following concentrated green tea extract supplementation, typically at doses of 700-2000+ mg EGCG daily, often in fasted state, and particularly in weight loss supplement contexts. Most affected individuals recover with supplement discontinuation; rare cases have progressed to liver failure requiring transplantation. Risk factors include: (1) high daily doses (>800 mg EGCG), (2) fasted administration, (3) concentrated high-purity extracts versus whole green tea or matcha, (4) combination with alcohol or other hepatotoxic substances, (5) individual genetic susceptibility (not fully characterized). Important contrast: green tea beverage consumption (even 8-10 cups daily) and moderate supplementation (200-400 mg EGCG daily with food) have an excellent safety record without hepatotoxicity signals. Practical recommendations: (1) limit supplement EGCG to 400-500 mg daily for most healthy users, maximum 800 mg; (2) always take with food, never fasted; (3) prefer standardized products from reputable brands over unverified weight loss supplements; (4) obtain baseline liver function panel before high-dose supplementation and every 3-6 months during use; (5) discontinue immediately if symptoms of jaundice, dark urine, severe fatigue, or upper abdominal pain develop; (6) avoid combining with alcohol or high-dose acetaminophen. Green tea beverage consumption at dietary levels remains one of the safest health practices globally.

Different green tea preparations provide different EGCG content and overall catechin profiles. Standard brewed green tea: approximately 50-100 mg EGCG per cup (8 oz) depending on steep time, temperature, and tea quality; well-studied safety; typical daily consumption of 2-5 cups provides 100-500 mg EGCG with natural caffeine and L-theanine. Matcha green tea: whole-leaf powder consumption provides 3-10x more catechins per serving than brewed tea; a half-teaspoon matcha serving provides 50-70 mg EGCG plus higher L-theanine content; the shade-grown cultivation process enhances L-theanine content. Decaffeinated green tea: removes caffeine (via solvent or CO2 extraction) while preserving most catechins; good option for caffeine-sensitive users; slight reduction in EGCG content versus regular green tea. Standardized green tea extract (50-80% polyphenols): provides concentrated EGCG in capsule form (typically 200-500 mg EGCG per serving); commercial efficiency but higher hepatotoxicity risk at extreme doses. Polyphenon E and Teavigo: pharmaceutical-grade and research-grade standardized extracts used in clinical trials. Purified EGCG (>90%): highest concentration per milligram but highest hepatotoxicity risk. Practical recommendation: for most users seeking health benefits, 2-4 cups daily green tea or 1-2 matcha servings daily provides excellent EGCG intake with optimal safety and cost. For users wanting convenience or specific therapeutic targets, standardized green tea extract at 200-400 mg EGCG daily is a reasonable alternative. Reserve high-purity EGCG supplements for specific clinical contexts with medical supervision.

EGCG produces modest weight loss effects, with meta-analyses showing approximately 1-2 kg additional weight loss over 12 weeks compared to placebo in overweight/obese adults. The effect is modest — roughly 10-20% of the weight loss achievable with substantial caloric restriction and exercise. EGCG is not a standalone weight loss treatment but can serve as a modest adjunct to lifestyle modifications. The weight loss mechanism combines: (1) increased fat oxidation through AMPK activation and COMT inhibition, (2) modest thermogenesis enhancement (particularly with caffeine co-administration), (3) modest reduction in glucose and fat absorption from meals, (4) possible appetite modulation. Practical protocols: standard weight loss dose is 400-500 mg EGCG + 100-200 mg caffeine taken 30-60 minutes before two or three daily meals. Combined with 500-750 calorie daily deficit and exercise, produces modestly enhanced weight loss over 12+ weeks. Important considerations: (1) EGCG alone without caloric modification produces minimal weight loss; (2) tolerance may develop with chronic use; (3) hepatotoxicity risk is elevated at higher doses — do not exceed 800 mg EGCG daily; (4) individual response varies substantially; (5) weight loss from EGCG + caffeine is largely through fluid loss and modest fat oxidation rather than muscle-preserving effects. Realistic expectations: EGCG supplementation may improve weight loss program outcomes by 1-2 kg over 12 weeks — meaningful but not transformative. Users should focus primarily on caloric intake and physical activity, with EGCG as a modest adjunct.

The population evidence is substantial and consistent. Multiple large cohort studies from Japan, China, and Korea have shown inverse associations between green tea consumption and cardiovascular mortality. The Ohsaki Study (Kuriyama 2006, PMID 16968850) followed 40,530 Japanese adults and found 16% reduced cardiovascular mortality at 5+ cups daily. The Ikeda et al study showed similar associations. Stroke mortality is more strongly reduced than coronary heart disease mortality in some analyses. However, population associations do not prove causation — green tea consumers may have other healthy behaviors correlated with their tea consumption. Randomized controlled trials of green tea or EGCG supplementation for cardiovascular outcomes (not just biomarkers) are limited due to the large sample sizes and long follow-up required. The biomarker evidence supports plausible mechanisms: modest blood pressure reduction (2-3 mmHg), LDL cholesterol reduction (3-5 mg/dL), improved endothelial function, reduced oxidative stress, anti-inflammatory effects. These biomarker effects are consistent with the observed population-level mortality reduction. Practical implications: (1) regular green tea consumption (2-4 cups daily) is associated with cardiovascular benefit and is among the safest health-promoting dietary practices; (2) supplementation (200-400 mg EGCG daily) provides the documented biomarker effects; (3) the overall evidence is strong enough to recommend green tea as a cardiovascular-supportive beverage alongside standard prevention (diet, exercise, blood pressure control, lipid management); (4) green tea is not a replacement for established cardiovascular medications when medically indicated.

EGCG has extensive preclinical chemoprevention evidence across multiple cancer types (breast, prostate, colon, lung, skin, bladder), with mechanisms including 67LR binding, kinase inhibition, HDAC and DNMT inhibition, apoptosis induction in transformed cells, antiangiogenic effects, and anti-inflammatory effects. Clinical translation is more limited. The best clinical evidence is the Bettuzzi 2006 (PMID 16425298) trial in men with high-grade prostatic intraepithelial neoplasia (HGPIN — a precursor to prostate cancer) where EGCG 600 mg daily (as Polyphenon E) for 1 year was associated with reduced progression to prostate cancer (3% progression in EGCG group versus 30% in placebo). Subsequent replication attempts have shown mixed results. Other trials in breast, colon, and bladder cancers have shown biomarker effects (tumor marker reductions, oxidative DNA damage) but not definitive disease-modifying outcomes. Veregen (polyphenon E topical) is FDA-approved for genital warts — a specific topical application with strong clinical evidence. Practical recommendations: (1) EGCG is appropriately positioned as a chemopreventive-oriented phytochemical with strong preclinical evidence and moderate clinical biomarker evidence; (2) not a standalone cancer prevention or treatment strategy — evidence-based screening (colonoscopy, mammography, PSA), lifestyle factors (tobacco avoidance, weight management, physical activity), and established preventive measures remain primary; (3) for users with cancer history or at elevated risk, discussion with oncology team about EGCG and green tea is reasonable; (4) avoid high-dose EGCG supplementation as a specific cancer prevention strategy without medical supervision due to hepatotoxicity concerns; (5) regular green tea consumption as part of a healthy diet is consistent with chemopreventive-oriented nutrition.

Green tea and warfarin interactions involve two mechanisms. First, green tea contains vitamin K, which antagonizes warfarin's effect. Second, EGCG has mild antiplatelet activity. The net effect depends on consistency of consumption. The practical recommendations are: (1) consistent daily green tea consumption (same number of cups daily, same type of tea) is manageable — your warfarin dose will be titrated by your INR to achieve target therapeutic range accounting for your typical green tea intake; (2) inconsistent green tea consumption (varying daily intake, starting or stopping suddenly) causes unpredictable INR fluctuations and increases bleeding or clotting risk; (3) high-dose EGCG supplementation is less predictable and generally not recommended on warfarin therapy; (4) direct oral anticoagulants (DOACs — apixaban, rivaroxaban, edoxaban, dabigatran) do not have the vitamin K interaction and are more forgiving of varied green tea consumption; (5) always inform your anticoagulation clinic or prescribing physician about your typical green tea and supplement use. If you are on warfarin and typically drink green tea: maintain your usual daily intake consistently; any change in consumption requires INR monitoring and possible dose adjustment. If you are considering adding green tea: discuss with your prescribing physician and monitor INR closely during the transition.

Yes, EGCG substantially reduces non-heme iron absorption — up to 50% reduction when taken with iron-containing meals or supplements. The mechanism is iron chelation by EGCG's catechol groups, forming insoluble complexes that cannot be absorbed. Heme iron (from meat sources) is less affected but still somewhat reduced. Clinical significance varies by individual iron status: (1) individuals with good iron stores typically tolerate green tea with meals without developing iron deficiency; (2) individuals with borderline iron status, menstruating women, vegetarians, frequent blood donors, or those already iron-deficient can develop clinically significant iron deficiency with high-dose EGCG combined with suboptimal dietary iron; (3) competitive athletes with high iron turnover are at particular risk. Practical recommendations: (1) separate timing between EGCG or green tea and iron-containing meals by at least 1-2 hours if iron status is a concern; (2) take iron supplements at least 1-2 hours before or after green tea/EGCG; (3) monitor iron status (ferritin, CBC) annually during high-dose EGCG supplementation; (4) consume iron-rich foods separately from tea — breakfast with fortified cereal and orange juice is fine, while tea with meals containing iron-rich spinach reduces iron absorption from that meal; (5) vitamin C enhances non-heme iron absorption and can partially offset EGCG's chelation effect when taken together; (6) for users with iron deficiency anemia, significantly reduce EGCG intake or take only separately from iron sources until iron stores are restored.

For most health benefits, yes — daily green tea consumption provides meaningful EGCG intake with optimal safety profile. Population studies showing cardiovascular mortality reduction are based on green tea beverage consumption, not supplementation. Dietary green tea at 2-5 cups daily provides 100-500 mg EGCG along with L-theanine, caffeine (or not in decaf), other catechins, and plant matrix components that may have independent or synergistic effects. Green tea also provides the ritualistic and contemplative aspects of tea consumption that are difficult to replicate with capsules. Supplementation becomes preferable in specific contexts: (1) users who don't enjoy tea preparation or consumption; (2) need for higher doses than dietary consumption reasonably provides (e.g., for weight management at 400-500 mg EGCG); (3) desire for standardized dosing; (4) dietary restrictions or caffeine sensitivity (use decaffeinated green tea extract); (5) specific clinical applications requiring consistent therapeutic doses. For most users seeking general health benefits, daily green tea consumption is the preferred approach — more enjoyable, less costly, safer, and backed by the strongest population-level evidence. For users wanting convenience or specific therapeutic effects, moderate-dose standardized extracts (200-400 mg EGCG daily) with food are a reasonable alternative.

These are overlapping but distinct categories. Polyphenols: large class of plant compounds characterized by multiple phenolic rings and hydroxyl groups. Includes thousands of different molecules across flavonoids, stilbenes, lignans, and other subclasses. Flavonoids: major polyphenol subclass; includes flavonols (quercetin, fisetin), flavones (apigenin), flavanols/catechins, anthocyanins, and others. Catechins (or flavanols): flavonoid subclass characterized by saturated three-ring flavan core; includes EGCG, EGC, ECG, EC (all found in green tea) plus related compounds in other plants. EGCG (epigallocatechin gallate): specific catechin with gallate ester modification; most abundant and studied catechin in green tea. Antioxidants: functional category (not structural) — molecules that prevent or reduce oxidative damage. Includes many polyphenols and catechins but also vitamin C, vitamin E, glutathione, CoQ10, alpha-lipoic acid, carotenoids, and other non-polyphenol compounds. Practical implications: (1) a green tea extract labeled '80% polyphenols' provides a higher total polyphenol content but may not specify EGCG content — compare products by specific EGCG content for clinical relevance; (2) whole green tea contains multiple catechins beyond just EGCG — the natural matrix provides synergistic effects in many studies; (3) antioxidant capacity measurement (ORAC, FRAP, TEAC) provides a general antioxidant comparison but does not predict specific clinical effects; (4) EGCG-specific effects (like 67LR binding, weight management) may differ from effects of other catechins or polyphenols; (5) for users seeking broad health benefits, whole green tea with its natural catechin spectrum is often better than purified EGCG for everyday use; for users seeking specific therapeutic doses, standardized EGCG is more efficient.

EGCG can be taken daily for most users, with duration depending on the intended application. For foundation cardiovascular and general health support, daily green tea or moderate-dose extract (200-400 mg EGCG) is appropriate indefinitely — there is no established need for cycling. The extensive population data supports decades of regular green tea consumption without concerning safety signals. For weight management adjunct use, EGCG + caffeine cycles of 8-12 weeks with 2-4 week breaks are reasonable to assess efficacy and prevent tolerance. For specific clinical applications (prostate cancer research, diabetes research), protocols typically specify 12-24 week durations followed by clinical reassessment. Important considerations: (1) annual liver function monitoring is prudent at doses above 400 mg EGCG daily for sustained long-term use; (2) if you experience any gastrointestinal issues, fatigue, or other symptoms that might suggest liver effects, reduce dose or take a break for 4-8 weeks and reassess; (3) some users prefer periodic breaks for personal reasons; this is not clinically necessary but is not harmful; (4) effects are reversible with discontinuation — lipid profile, blood pressure, and biomarker effects gradually return to baseline over weeks to months without EGCG. Discontinuation considerations: no withdrawal syndrome occurs with EGCG cessation. Users can start, stop, and restart without special tapering. For individuals with documented liver disease or other contraindications, EGCG supplementation should be avoided entirely or only with specialist supervision.